Tags

Type your tag names separated by a space and hit enter

Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
J Glaucoma. 2010 Jun-Jul; 19(5):331-5.JG

Abstract

PURPOSE

To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost.

PATIENTS AND METHODS

In this prospective, 4-week, randomized, open-label controlled clinical trial, patients with open-angle glaucoma or ocular hypertension, which presented at least 15% intraocular pressure (IOP) reduction after a minimum period of 15 days of monotherapy with latanoprost and whose IOP level was considered above the established target-IOP level were randomized to receive fixed combination of timolol/dorzolamide twice daily in one of eyes. The fellow eye was kept under monotherapy and was included in the control group. A modified diurnal tension curve (mDTC) followed by the water drinking test were performed in the baseline and week 4 visits to evaluate IOP profile between groups.

RESULTS

Forty-nine per-protocol patients were analyzed. After latanoprost monotherapy run-in period, IOP levels were significantly reduced (P<0.001) in both control and study groups to 15.34+/-2.96 mm Hg and 15.24+/-2.84 mm Hg (30.8% and 32.2% IOP reduction, respectively; P=0.552). At week 4, mean baseline diurnal IOP levels were 15.60+/-3.09 and 14.44+/-3.03 (7.4% difference; P=0.01). Mean baseline IOP modified diurnal tension curve peak after latanoprost run-in period were 17.47+/-3.68 mm Hg and 17.02+/-3.35 mm Hg (control and study eyes, respectively; P=0.530). At week 4 visit, mean water-drinking test peaks were significantly reduced in the study eye group in comparison with the control group: 19.02+/-3.81 mm Hg and 20.39+/-4.19 mm Hg, respectively (6.7% reduction; P=0.039).

CONCLUSIONS

In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction.

Authors+Show Affiliations

Department of Ophthalmology, School of Medicine, University of Sao Paulo, Brazil. info@centroavancado.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19730119

Citation

Hatanaka, Marcelo, et al. "Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/dorzolamide 2% (Cosopt) On Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: a Prospective, 4-week, Open-label, Randomized, Controlled Clinical Trial." Journal of Glaucoma, vol. 19, no. 5, 2010, pp. 331-5.
Hatanaka M, Reis A, Sano ME, et al. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. J Glaucoma. 2010;19(5):331-5.
Hatanaka, M., Reis, A., Sano, M. E., & Susanna, R. (2010). Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. Journal of Glaucoma, 19(5), 331-5. https://doi.org/10.1097/IJG.0b013e3181b4cab4
Hatanaka M, et al. Additive Intraocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/dorzolamide 2% (Cosopt) On Monotherapy With Latanoprost (Xalatan) in Patients With Elevated Intraocular Pressure: a Prospective, 4-week, Open-label, Randomized, Controlled Clinical Trial. J Glaucoma. 2010 Jun-Jul;19(5):331-5. PubMed PMID: 19730119.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. AU - Hatanaka,Marcelo, AU - Reis,Alexandre, AU - Sano,Milena Eimi, AU - Susanna,Remo,Jr PY - 2009/9/5/entrez PY - 2009/9/5/pubmed PY - 2010/9/25/medline SP - 331 EP - 5 JF - Journal of glaucoma JO - J. Glaucoma VL - 19 IS - 5 N2 - PURPOSE: To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost. PATIENTS AND METHODS: In this prospective, 4-week, randomized, open-label controlled clinical trial, patients with open-angle glaucoma or ocular hypertension, which presented at least 15% intraocular pressure (IOP) reduction after a minimum period of 15 days of monotherapy with latanoprost and whose IOP level was considered above the established target-IOP level were randomized to receive fixed combination of timolol/dorzolamide twice daily in one of eyes. The fellow eye was kept under monotherapy and was included in the control group. A modified diurnal tension curve (mDTC) followed by the water drinking test were performed in the baseline and week 4 visits to evaluate IOP profile between groups. RESULTS: Forty-nine per-protocol patients were analyzed. After latanoprost monotherapy run-in period, IOP levels were significantly reduced (P<0.001) in both control and study groups to 15.34+/-2.96 mm Hg and 15.24+/-2.84 mm Hg (30.8% and 32.2% IOP reduction, respectively; P=0.552). At week 4, mean baseline diurnal IOP levels were 15.60+/-3.09 and 14.44+/-3.03 (7.4% difference; P=0.01). Mean baseline IOP modified diurnal tension curve peak after latanoprost run-in period were 17.47+/-3.68 mm Hg and 17.02+/-3.35 mm Hg (control and study eyes, respectively; P=0.530). At week 4 visit, mean water-drinking test peaks were significantly reduced in the study eye group in comparison with the control group: 19.02+/-3.81 mm Hg and 20.39+/-4.19 mm Hg, respectively (6.7% reduction; P=0.039). CONCLUSIONS: In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction. SN - 1536-481X UR - https://www.unboundmedicine.com/medline/citation/19730119/Additive_intraocular_pressure_reduction_effect_of_fixed_combination_of_maleate_timolol_0_5/dorzolamide_2__Cosopt__on_monotherapy_with_latanoprost__Xalatan__in_patients_with_elevated_intraocular_pressure:_a_prospective_4_week_open_label_randomized_controlled_clinical_trial_ L2 - http://dx.doi.org/10.1097/IJG.0b013e3181b4cab4 DB - PRIME DP - Unbound Medicine ER -